VILINBIO
SME CapVILIN BIO MED LTD.
Pharma
VILIN BIO MED LTD. operates in Medical Devices, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, management trust needs verification, price trend is neutral, and recent execution is weak.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Good · 55/100Rev +300% YoY · margin expansion · +237% QoQ
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹32.6 Cr | +299.5% | +237.5% |
| EBITDA | ₹2.9 Cr | +673.0% | +741.2% |
| Operating margin | 8.8% | +518 bps | +525 bps |
| PAT | ₹1.8 Cr | NDF | +1086.7% |
| PAT margin | 5.5% | +449 bps | +391 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Issuer presentation review pending
VILIN BIO MED LTD. operates in Medical Devices, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trend score and candlestick chart
51Neutralnear 52W high
Technical chart
VILINBIOweekly · 3Y+116.9%Technical trend read
NeutralTrend is undirectional — long-term trend unclear. RSI 76.
- RSI(14) at 76 — overbought zone; risk of mean reversion.
- MACD below signal but histogram contracting — bearish momentum easing.
- 10% off 52W high · 157% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
WATCHLISTWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 7/9.
- Growth contributes 20/25 to the score.
- Balance sheet contributes 11/15 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Quality is weaker at 1/20; verify the latest quarterly trend.
- Valuation is weaker at 4/30; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Weak Trust: Claim history is still being built. It ranks around the 9th percentile of the scored universe and 5th percentile within Pharma. Main check: results consistency is weak at 29/100.
Mixed Trust Lite: Promoter holding is 59.6%. Key concern: 4 recent quarters had PAT decline worse than 25% YoY.
Management or financial behaviour needs caution. Demand stronger valuation compensation.
overall median 67 · Pharma: 5th pctile, median 70 · SME: 7th pctile, median 65
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Weak Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 59.6%.
- ▸Promoter pledge is zero.
- ▸Debt/equity is 0.02.
- ▸4/4 recent quarters had positive YoY revenue growth.
Trust risks
- ▸4 recent quarters had PAT decline worse than 25% YoY.
- ▸Promoter holding fell 4.3%.
- ▸Only 1 years of positive FCF.
- ▸Interest coverage is 1.4x.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- 38.40
- P/B
- 2.61
- EV/EBITDA
- 21.38
- Market Cap
- 74.20Cr
Profitability
- ROE
- 7.51%
- ROCE
- 10.80%
- ROA
- 5.52%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 30.00%
- EPS 5Y
- 74.00%
- Revenue 3Y
- 51.00%
- EPS 3Y
- 16.00%
Balance Sheet
- Debt/Equity
- 0.01
- Interest Coverage
- 45.71×
- Altman Z
- 8.33
- Book Value
- 18.60
Cash Flow
- FCF Yield
- 0.54%
- FCF Positive Y
- 2/5
- OCF
- 0.70 Cr
- EPS TTM
- 1.27
Shareholding
- Promoter Hold
- 56.65%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 84%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.